STAAR Surgical (NASDAQ:STAA) Given Consensus Recommendation of “Hold” by Brokerages

Shares of STAAR Surgical (NASDAQ:STAA) have received an average rating of “Hold” from the ten brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $25.29.

STAA has been the subject of several research analyst reports. BTIG Research downgraded shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 12th. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a report on Thursday, February 27th. Stephens reiterated an “equal weight” rating and set a $17.00 price target on shares of STAAR Surgical in a report on Tuesday, March 18th. StockNews.com downgraded STAAR Surgical from a “hold” rating to a “sell” rating in a research note on Thursday, February 13th. Finally, William Blair cut STAAR Surgical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th.

Insider Transactions at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 8,221 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were bought at an average price of $21.50 per share, for a total transaction of $176,751.50. Following the purchase, the insider now directly owns 10,878,007 shares in the company, valued at $233,877,150.50. This trade represents a 0.08 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders bought 1,074,103 shares of company stock valued at $17,900,948 in the last three months. Corporate insiders own 1.00% of the company’s stock.

Institutional Investors Weigh In On STAAR Surgical

A number of large investors have recently bought and sold shares of the business. Broadwood Capital Inc. lifted its position in shares of STAAR Surgical by 0.7% in the fourth quarter. Broadwood Capital Inc. now owns 10,848,631 shares of the medical instruments supplier’s stock worth $263,513,000 after buying an additional 80,200 shares during the last quarter. Vanguard Group Inc. lifted its holdings in STAAR Surgical by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock worth $142,232,000 after purchasing an additional 319,441 shares during the last quarter. State Street Corp boosted its position in STAAR Surgical by 0.5% during the third quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier’s stock worth $72,092,000 after purchasing an additional 10,430 shares during the period. Resona Asset Management Co. Ltd. acquired a new position in STAAR Surgical during the fourth quarter valued at approximately $36,411,000. Finally, Geode Capital Management LLC raised its position in shares of STAAR Surgical by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock valued at $43,641,000 after purchasing an additional 31,212 shares during the period. 96.70% of the stock is currently owned by institutional investors.

STAAR Surgical Trading Up 1.3 %

STAA stock opened at $17.79 on Friday. STAAR Surgical has a one year low of $13.50 and a one year high of $52.68. The firm has a 50-day moving average of $19.43 and a two-hundred day moving average of $25.23. The firm has a market capitalization of $877.49 million, a PE ratio of -43.39 and a beta of 0.66.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.